Grail Inc

GRAL remains in a Stage 2 advancing uptrend with higher highs & higher lows intact above the rising 50-day and 200-day SMAs. A Bullish Exhaustion signal at recent highs signals weakening upside momentum, and price is currently retracing into the 9-day and 20-day EMAs. A pullback into the 20-day EMA / 50-day SMA support zone offers a tactical entry, but execution is deferred pending acceptance around these levels.

• ↑Q2’26 revenue $44.7M (+26% YoY); Galleri tests rose 35% to 61K
• ↑Galleri FDA advisory panel set for Sep 23 2026, boosting market access prospects
• ↓Q2’26 net loss $110.2M on sustained cash burn, raising funding needs